Published in BMC Cancer on September 13, 2010
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49
A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science (2001) 31.33
Nuclear export of microRNA precursors. Science (2003) 16.59
Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell (2002) 10.30
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A (2003) 8.73
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
Sequence requirements for micro RNA processing and function in human cells. RNA (2003) 7.46
Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J (2002) 6.65
Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol (1992) 3.39
The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+. J Virol (1990) 3.16
Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res (2006) 2.93
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis (2003) 2.68
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther (2008) 2.66
Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev (2008) 2.52
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 2.05
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A (2001) 1.99
Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. J Virol (1985) 1.77
Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol (1991) 1.77
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther (2007) 1.75
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70
Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs (2010) 1.57
VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res (2001) 1.55
HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol (1994) 1.53
Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res (2005) 1.51
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res (2005) 1.45
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res (1997) 1.45
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A (1995) 1.41
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A (1996) 1.41
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27
TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets (2006) 1.24
The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery (2003) 1.17
Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res (2007) 1.13
Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther (1999) 1.13
Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther (1999) 1.12
Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther (2008) 1.09
Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology (2005) 1.09
Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg (2001) 1.06
Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun (2003) 1.05
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res (2006) 1.02
Lentivirus-mediated silencing of Tiam1 gene influences multiple functions of a human colorectal cancer cell line. Neoplasia (2006) 1.01
Advances in the development of siRNA-based therapeutics for cancer. IDrugs (2008) 1.01
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer (2005) 1.01
Post-transcriptional processing of cellular RNAs in herpes simplex virus-infected cells. Biochem Soc Trans (2004) 1.01
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther (2005) 1.01
Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A (2001) 0.94
Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther (2005) 0.94
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate (2002) 0.93
Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer (2004) 0.93
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res (2008) 0.93
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med (2007) 0.92
A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery (2002) 0.90
Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med (2003) 0.89
Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol (2005) 0.86
Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res (2004) 0.83
Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther (2001) 0.82
Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. J Dig Dis (2008) 0.82
Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. Gene Ther (2006) 0.81
Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J (Engl) (2005) 0.80
HIV-1-mediated delivery of a short hairpin RNA targeting vascular endothelial growth factor in human retinal pigment epithelium cells. Br J Ophthalmol (2009) 0.79
RNA interference of IL-10 in leukemic B-1 cells. Cancer Immun (2004) 0.78
Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg (2004) 0.78
Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. Surgery (2004) 0.78
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis (2003) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res (2007) 1.38
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regions. J Gen Virol (2002) 1.34
Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer (2010) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics (2004) 1.12
Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion. J Immunol (2004) 1.11
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol (2008) 1.09
Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol (2003) 1.08
Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res (2007) 1.08
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother (2011) 1.04
Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab (2006) 1.04
Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated migration. J Gen Virol (2005) 1.04
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome. J Virol (2007) 1.03
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res (2006) 1.02
HOX genes in ovarian cancer. J Ovarian Res (2011) 0.99
ATF3 upregulation in glia during Wallerian degeneration: differential expression in peripheral nerves and CNS white matter. BMC Neurosci (2004) 0.99
Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther (2008) 0.99
Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat (2012) 0.97
HOX genes in pancreatic development and cancer. JOP (2011) 0.96
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res (2008) 0.93
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia. Neurosurgery (2007) 0.91
Targeting HOX transcription factors in prostate cancer. BMC Urol (2014) 0.89
The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Int J Cancer (2013) 0.89
Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res (2008) 0.88
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 0.88
Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurons of the hippocampus against kainic-acid-induced cell loss. Brain Res Mol Brain Res (2003) 0.87
Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res (2008) 0.85
Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther (2010) 0.85
A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow. Clin Cancer Res (2006) 0.82
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther (2010) 0.82
Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncol (2011) 0.80
Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virus. Expert Opin Biol Ther (2010) 0.80
Gene therapy for head and neck cancer. Cancer Metastasis Rev (2005) 0.80
Impact of process conditions on the centrifugal recovery of a disabled herpes simplex virus. Biotechnol Prog (2003) 0.78
Oncolytic viruses: do they have a role in anti-cancer therapy? Clin Med Oncol (2008) 0.78
Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression. Pigment Cell Melanoma Res (2013) 0.77
Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control. Methods Mol Biol (2009) 0.77
Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol Immunother (2003) 0.76
Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2010) 0.76
Oncolytic herpes simplex virus for tumor therapy. Int Rev Neurobiol (2003) 0.75
Construction of multiply disabled herpes simplex viral vectors for gene delivery to the nervous system. Methods Mol Med (2003) 0.75
The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int (2008) 0.75